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Inactive alleles of cytochrome P450 2C19 may be
positively selected in human evolution
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Abstract
Background: Cytochrome P450 CYP2C19 metabolizes a wide range of pharmacologically active substances and a
relatively small number of naturally occurring environmental toxins. Poor activity alleles of CYP2C19 are very
frequent worldwide, particularly in Asia, raising the possibility that reduced metabolism could be advantageous in
some circumstances. The evolutionary selective forces acting on this gene have not previously been investigated.
We analyzed CYP2C19 genetic markers from 127 Gambians and on 120 chromosomes from Yoruba, Europeans and
Asians (Japanese + Han Chinese) in the Hapmap database. Haplotype breakdown was explored using bifurcation
plots and relative extended haplotype homozygosity (REHH). Allele frequency differentiation across populations was
estimated using the fixation index (FST) and haplotype diversity with coalescent models.
Results: Bifurcation plots suggested conservation of alleles conferring slow metabolism (CYP2C19*2 and *3). REHH
was high around CYP2C19*2 in Yoruba (REHH 8.3, at 133.3 kb from the core) and to a lesser extent in Europeans
(3.5, at 37.7 kb) and Asians (2.8, at −29.7 kb). FST at the CYP2C19 locus was low overall (0.098). CYP2C19*3 was an FST
outlier in Asians (0.293), CYP2C19 haplotype diversity < = 0.037, p <0.001.
Conclusions: We found some evidence that the slow metabolizing allele CYP2C19*2 is subject to positive selective
forces worldwide. Similar evidence was also found for CYP2C19*3 which is frequent only in Asia. FST is low at the
CYP2C19 locus, suggesting balancing selection overall. The biological factors responsible for these selective
pressures are currently unknown. One possible explanation is that early humans were exposed to a ubiquitous
novel toxin activated by CYP2C19. The genetic adaptation took place within the last 10,000 years which coincides
with the development of systematic agricultural practices.
Keywords: Positive selection, Cytochrome P450 2C19, Xenobiotics, Drug metabolism, Extended haplotype
homozygosity, Bifurcation plots
Background
The cytochrome P450 enzymes (hereafter referred to as
cytochromes) have a wide range of essential biological
functions in humans resulting from oxidation of their
substrates. CYP2C19 is a key member of the cytochrome
family and is responsible for metabolizing a substantial
proportion of pharmacologically important compounds
[1-8] although it is known to metabolize only a relatively
small number of environmental toxins [9,10]. The en-
zyme is encoded by the CYP2C19 gene which is situated
in the CYP2C gene cluster on chromosome 10 where it
is in strong linkage disequilibrium with CYP2C9 [11].
CYP2C19 exhibits considerable genetic polymorphism
giving rise to profound changes in enzyme activity leading
to reduced metabolic capacity [12]. This ‘poor metabolizer’
phenotype is common worldwide occurring at 0.02-0.05
in Caucasians and 0.18-0.23 in Asians [13,14]. However
the evolutionary mechanisms driving this remarkable al-
lelic diversity which have shaped the drug metabolizing
repertoire of modern humans have not previously been
investigated.
Early investigations into the genetic basis for the poor
metabolizer phenotype revealed a single base pair muta-
tion in exon 5 of CYP2C19 (19154G/A) which creates an
aberrant splice site altering the reading frame of the
mRNA and introducing a premature stop codon. This
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allele, designated CYP2C19*2, results in a non-functional
protein [15]. CYP2C19*2 is common in Europe (allele
frequency 0.16), Africa (0.14), China (0.26) and Japan
(0.28) [16] but does not completely account for the poor
metabolizer phenotype in Asia where another poor
metabolizing allele CYP2C19*3 is also common (0.08) [17].
CYP2C19*3 is rare in Europeans and Africans (0–0.01)
[17-20]. The molecular basis for CYP2C19*3 is a guanine
to adenine mutation at position 636 of exon 4 (636G/A)
which creates a premature stop codon downstream result-
ing in a non-functional protein. The prevalence of these
slow metabolizing alleles tends to increase moving east so
in some parts of East Asia CYP2C19*2 and *3 allele fre-
quencies rise to 0.71 and 0.13 respectively making the slow
metabolizer phenotype predominant [21]. CYP2C19 ultra-
rapid metabolism is conferred by a gain-of-function allele
(*17) (−806C >T, −3402C >T [22]) which is an important
determinant of the rate of metabolism of certain drugs
[19]. CYP2C19*17 occurs at a high frequency in Yoruba
(0.28), Gambians (0.24), Ethiopians and Swedish (0.18) and
is rare in Chinese (0.04) [19,22].
Because of a potential role in metabolizing unknown
environmental substances, alleles that cause a change in
function of the enzyme would be likely to give an indi-
vidual a selective advantage or disadvantage in evolu-
tionary terms. For example if the cytochrome is involved
in promoting the elimination of a toxic chemical, a gain-
of-function allele might confer evolutionary advantage
and would thus be positively selected. Conversely if the
enzyme catalysed the formation of a toxic compound
from an otherwise non-toxic precursor, then alleles con-
ferring low enzyme activity might be selected.
New techniques for identifying such selective pressures
on genes in specific populations have been developed lead-
ing to significant new insights into human genetic diver-
sity [23]. When a novel allele of a gene initially arises in a
population, it is associated with a single haplotype. If this
haplotype undergoes a rapid increase in frequency because
of positive selection, there is little time for recombination
events to break the ancestral links with nearby genetic
markers [24]. Hence recently selected alleles tend to dis-
play lower haplotypic diversity than do ancient alleles of
similar frequency. Thus exploring the length of stretches
of homozygosity (extended haplotype homozygosity or
EHH) is a way of detecting recent positive selection in the
human genome from haplotype structure. EHH is defined
as the probability that chromosomes from two randomly
chosen individuals are identical from a selected ‘core’
region to a point X. The core is usually selected as a
few single nucleotide polymorphisms (SNPs) around a
polymorphism that either causes a major functional change
in a protein or results in a particular phenotype and the
similarity between the chromosomes is measured by the
length of homozygosity of genetic markers.
In an extension of this idea, relative extended haplo-
type homozygosity (REHH) is the ratio of the EHH of
the core haplotype compared with the EHH of all other
haplotypes on the chromosome. The REHH test compares
the length of haplotype identity as a function of frequency
around each allele compared to an expected distribution
[25]. The degree of haplotype diversity can also be explored
graphically using bifurcation plots which are diagrams for
visualizing the breakdown of linkage disequilibrium (LD)
along haplotypes. These methods are complementary to
more conventional population based measures used to
examine whether differences in frequencies of markers in
specific ethnic groups may have arisen by chance [26].
Recent studies have highlighted the importance of in-
fectious agents such as malaria [23,27] and viral haemor-
rhagic fever [28,29] in shaping the human genome.
Similarly the challenges of adapting to the physical en-
vironment have left signals of positive selection in genes
related to skin pigmentation [30,31] and development of
hair follicles [32]. However there is little evidence to date
that potentially harmful chemical substances in the en-
vironment have exerted significant evolutionary selective
pressure.
In view of the key role of cytochrome P450 enzymes
in metabolism of environmental compounds, we investi-
gated the CYP2C19 locus for signatures of evolutionary
selection. We focussed specifically on the common non-
functional CYP2C19 mutations CYP2C19*2 (19154G/A)
and *3 (636G/A), measuring their haplotype frequencies
and molecular diversity across populations, aiming to
identify signals of recent evolutionary selection that might
result from exposure to potentially harmful environmental
substances.
Results
Analysis of extended haplotype homozygosity at the
CYP2C19 locus
Bifurcation plots for the common loss-of-function al-
lele CYP2C19*2 in the merged genotypic data from
Gambians are shown in Figure 1A. The haplotypes
for CYP2C19*2/*3-containing alleles are described in
Figure 2.
The bifurcation plot for the haplotype carrying
CYP2C19*2 (AGT) suggests some evidence of positive
selection, shown by the predominance of thick branches.
This haplotype, present at a frequency of 0.15, had an
REHH of 2.7 at −68.3 kb from the core region which is
supportive of the suggestion of positive selection for
CYP2C19*2. Since our genotyping data did not extend
further than −68.3 kb from the core haplotype it was not
possible to examine REHH over longer stretches of the
genome in the Gambian study group.
We therefore examined the HapMap data for the Yoruba
to obtain more extensive genomic data from people living
Janha et al. BMC Evolutionary Biology 2014, 14:71 Page 2 of 10
http://www.biomedcentral.com/1471-2148/14/71
in a nearby area of West Africa (Figure 1B). The same
CYP2C19*2 AGT-haplotype was present in the Yoruba at
a similar frequency to Gambians (0.14) and displayed ex-
tended homozygosity evidenced by conservation on the bi-
furcation plot and an REHH of 8.3 at 133.3 kb from
the core. This implies that the slow metabolism allele
can confer an evolutionary advantage and confirms
the initial findings in Gambians. The magnitude of the
REHH for CYP2C19*2 in Yoruba is similar to that ob-
served for G6PD-202A (glucose-6-phosphate dehydro-
genase deficiency) which is thought to confer a 50%
reduction in risk of malaria [23,33].
Analysis of CYP2C19*2 for positive selection in Euro-
peans showed similar patterns to those observed in Yor-
uba (Figure 3A). The AGT haplotype occurred at a similar
frequency (0.15) with an REHH value of 3.5 at 37.7 kb from
the core. The CYP2C19*2 bifurcation plot for Europeans
showed some breakdown of the haplotype depicted by the
thinning of the branch indicating the emergence of a new
mutation. These results provide some evidence for
CYP2C19*2 selection in Europeans, however the effect ap-
pears to be less strong than that observed in West Africans.
Japanese and Han Chinese had the highest CYP2C19*2
AGT frequency at 0.27 and the lowest REHH (2.8
at −29.7 kb from the core). The bifurcation plot for the
Japanese and Han Chinese showed clear breakdown of
haplotype homozygosity arising from development of
a new mutation, depicted by thinning of the branch
(Figure 3B). This suggests that CYP2C19*2 is not subject
to recent positive selection in this population. However in
contrast CYP2C19*3 (rs4986893), which also codes for an
inactive enzyme only found in Asia shows some evidence
of extended homozygosity (Figure 4A).
Interestingly, analysis for extended haplotype homozy-
gosity around the CYP2C19*17 allele in Gambians, Yor-
uba and Asians showed no evidence of selection. Only
Europeans demonstrated a signature of selection at the
CYP2C19*17 locus where the TTT-haplotype frequency
is high at 22% and its bifurcation plot does not break-
down the haplotype homozygosity despite the generation
of new SNPs from recombination events (Figure 4B).
Allele frequency differences for CYP2C19 across
populations from West Africa, Europe and Asia
FST at the CYP2C19 locus was low overall across the
three populations implying balancing selective forces
(Table 1). The FST for CYP2C19*2 (rs4244285) was 0.016
implying that only 1.6% of human genetic diversity at
Figure 1 Haplotype bifurcation plots and extended haplotype homozygosity diagrams for CYP2C19 slow metabolizing allele (*2) in
West Africans. The core for the haplotypes in the first four diagrams is centred at the genomic position of the CYP2C19*2 variant (SNP positions
rs4244285, rs4417205 and rs3758580) which is universally present and known to encode a functionally inactive protein. The upper part of each
diagram shows a haplotype bifurcation plot representing the degree to which a haplotype is broken down by the emergence of new mutations
in the gene. The lower graph shows relative homozygosity for each haplotype (depicted by the coloured lines, described in Figure 2) plotted
against genomic position. High values observed some distance from the core indicate extended homozygosity and suggest recent positive
evolutionary selection. Common core haplotypes and their frequencies are indicated in Figure 2. A. CYP2C19 haplotype structure in Gambians.
The CYP2C19*2 containing haplotype AGT (haplotype 2) is relatively conserved in the bifurcation plot as demonstrated by the single thick line
and by relatively few, thinner branches. There is some limited evidence of extended homozygosity. B. CYP2C19 haplotype structure in Yoruba.
The CYP2C19*2 containing haplotypes AGT (haplotype 2) and GGC (haplotype 4) both show conservation in the bifurcation plots and extended
haplotype homozygosity.
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CYP2C19*2 is a result of genetic differentiation among
the four populations studied. The CYP2C19*3 allele in
Japanese and Han Chinese had a high FST implying un-
opposed positive selection in this population. Pairwise FST
values are given in Additional file 1: Table S1. Coalescent
simulations of the genotypic data showed significant haplo-
type diversity < = 0.037 (p <0.001) for the CYP2C alleles
screened in the Gambians and HapMap populations.
Discussion
We found some evidence that non-functional haplotypes
of CYP2C19 (CYP2C19*2, CYP2C19*3) may be subject
to selective forces in recent human evolution. Slow
metabolizing haplotypes of CYP2C19 showed extended
homozygosity which results from recent positive selec-
tion. We inferred this initially in the Gambian popula-
tion for CYP2C19*2 and these findings were confirmed
by analysis of genotypic data in Yoruba, from a nearby
region of West Africa. We observed a similar pattern
of haplotype homozygosity in Europeans, however the
CYP2C19*2 EHH is more striking in Yoruba suggesting
stronger positive selection in the West African population.
Interestingly the fast metabolizing CYP2C19*17 was also
under positive selection in Europeans. The REHH statistic
observed for CYP2C19*2 in Yoruba (REHH 8.3) is of a
similar magnitude to that seen in the same ethnic group
for G6PD [23]. Selection pressure on G6PD is thought to
be due to protection from malaria which is a major cause
of death in childhood in Africa.
CYP2C19*2 accounts for the poor metabolizing
phenotype in Europeans and in people of African des-
cent, whilst CYP2C19*3 contributes to the poor
metabolizer phenotype only in Asia. In Asian populations
we found some evidence that CYP2C19*3 is also
positively selected. This suggests that the CYP2C19 poor
metabolism phenotype confers an evolutionary advantage
in Asia in addition to Africa and Europe even though some
alleles responsible for that phenotype differ between the
three continents.
All FST values estimated for the CYP2C19 SNPs are
lower than the average FST values for autosomal SNPs in
worldwide human populations which is approximately
0.123. The CYP2C19 FST values are consistent with the
low FST observed for many of the genes involved in im-
munity such as the major histocompatibility complex
(MHC) and beta-globin gene which are under balancing
selection [34]. The low FST is an indication that balan-
cing or species-wide directional selection has taken place
at the CYP2C19 locus, in contrast to the force of
geographically-restricted directional selection that leads
to high FST values. Thus one would infer from the long
extended haplotype and low FST for the slow-metabolizer
CYP2C19*2 allele that CYP2C19*2 is still evolving and has
not yet reached fixation.
Investigations of evolutionary selection of alleles in the
CYP2C cluster in the past have been relatively limited.
Vormfelde and colleagues analysed selection signals
in CYP2C9 [1] and showed that the low activity allele
CYP2C9*3 appeared to be under positive selection. There
is a high degree of Linkage Disequilibrium (LD) in the
CYP2C cluster so it is possible that the effects we saw on
CYP2C19 might reflect selection of alleles of CYP2C9 and
CYP2C8 [11] however the extended haplotypes that we
found did not stretch beyond the CYP2C19 genomic re-
gion. CYP2C9*3 was not screened in this project as the
variant has not been found in sub Saharan Africa.
Our finding of positive selection for CYP2C19*2 poor
functional variant worldwide is in accordance with the
dbSNP rs ID rs4244285 rs4417205 rs3758580
Wildtype G C G Gambians Yoruba Europeans Asians
Haplotype 1 . . C 73 80 85 73
Haplotype 2 A G T 15 14 15 27
Haplotype 3 A . C 7 3 0 0
Haplotype 4 . G C 4 3 0 0
Haplotype 5 . G T 1 0 0 0
Haplotype 6 A G C 0 0 0 0
dbSNP rs ID rs12778026 rs4986893 rs4304692
Wildtype A G G
Haplotype 1 T . G 62
Haplotype 2 A . G 27
Haplotype 3 T . A 7
Haplotype 4 T A A 4CY
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Figure 2 CYP2C19 poor metabolism haplotypes and their frequencies in the study populations. Sweep 1.1 was used to determine
haplotypes and extended haplotype homozygosity at the CYP2C19*2 locus from 500 individuals including Gambians and HapMap populations.
CYP2C19*3 was found only in the Asian population.
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recent findings by Pimenoff and colleagues who used
a similar technique (EHH) and haplotype structure to
describe selection pressure on poor activity variants
CYP2C19*2 and CYP2C9*3 in Europeans [35]. Our
study further highlights CYP2C19*3 to be under selective
pressure in Asians and the high activity CYP2C19*17 in
Europeans. Poor activity alleles especially are favoured in
recent human evolution, being selected in Africa, Europe
and Asia. A further analysis of cytochrome gene evolu-
tionary selection in the indigenous American populations
would give interesting additional information.
Time scale of the evolutionary processes
The population selection forces acting on CYP2C19 alleles
are likely to have been operating over the last 10,000 years
[23,36]. An allele under positive selection rapidly rises in
prevalence such that recombination does not substantially
break down the association with alleles at nearby loci on
the ancestral chromosome. This characteristic of an allele
under positive selection is short-lived because recombin-
ation rapidly breaks down the long-range haplotypes.
Possible biological factors causing selective pressure on
inactive CYP2C19 alleles
It is interesting to speculate what biological forces are
responsible for evolutionary selection of inactive alleles
of CYP2C19. The period of selection would be likely to
correspond with the end of the most recent glacial age
and beginning of the Mesolithic era (Middle Stone Age),
from 8500 BC to 4000 BC. Over this period there is sub-
stantial archaeological evidence of developing systematic
agricultural practices in Asia and the Middle East in
contrast to the previous hunting and gathering lifestyle
of early humans [37].
The storage of grain and tubers from one growing sea-
son to another, which is essential for effective agricul-
ture, would have exposed early humans to a range of
novel toxins derived from fungi growing on stored food-
stuffs. Activation of mycotoxins by cytochrome P450 en-
zymes is well-described [38,39] and these toxins remain
a major health problem in Sub Saharan Africa to the
present day. Recently, CYP2C19 has been implicated in
the metabolism of the cytotoxic mycotoxin enniatin B, a
very stable secondary fungal metabolite of Fusarium
strains that contaminate cereals and grains [40].
In addition to mycotoxins, other classes of harmful en-
vironmental compounds may have been encountered for
the first time as a result of developing agricultural prac-
tices. For example aryl hydrocarbons formed from in-
complete combustion of carbon are highly toxic when
partially activated by CYP2C19 and might be produced
by the use of fire to clear land for crops [10].
Earlier speculations by Nebert suggested that rapid
evolution of drug metabolizing enzyme (DME) genes
and receptor genes occurred as a result of the inter-
action between animals as they moved on to land and
the plants that they encountered there. An explosion of
new animal genes in the CYP2 family occurred nearly
400 million years ago with more than 50 gene duplica-
tion events [41]. Nelson and colleagues argue that CYP
evolution started much earlier >600 million years ago at
the same gene locus referred to as the cytochrome P450
genesis locus from where all CYP clans or families
emerged [42]. The DME genes then further evolved to
produce polymorphic enzymes that may have functions
Figure 3 Haplotype bifurcation plots and extended haplotype homozygosity diagrams for CYP2C19 slow metabolizing allele (*2) in
Europeans and Asians. A. CYP2C19 haplotype structure in Europeans. CYP2C19*2 containing AGT (haplotype 2) shows a branching pattern and
the level of extended homozygosity is lower than observed in Yoruba. B. CYP2C19*2 haplotype structure in Japanese and Han Chinese. The
CYP2C19*2-containing haplotype AGT (haplotype 2) has a branching structure and REHH values similar to those in Europeans.
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diminished or enhanced as a consequence of selection
of alleles perhaps in response to diet [43]. Such factors
may give rise to the selective pressures that maintain
the high frequency of the poor metabolizing alleles of
CYP2C19*2/*3 [42-44].
The physiological functions of CYP2C19, particularly
in the synthesis of steroid hormones, could also poten-
tially be important in increasing survival fitness [45].
Gomes and colleagues in 2009 implicated CYP2C19/
CYP3A4 in 21-hydroxylation of progesterone in individ-
uals with 21-hydroxylase deficiency thus affecting levels
of mineralocorticoids [46]. A recent study has linked
CYP2C19*2 rs4244285 with the regulation of blood pres-
sure [47]. CYP2C19 may also influence arachidonic acid
metabolism predisposing to peptic ulcer disease [48,49]
and vascular disease [50]. These functions might also
influence the interaction with environmental pathogens
although the mechanism by which the resulting selective
force might operate and the strength of the selective
pressure that would result is not clear.
Whilst the mechanism for positive selection of individ-
uals with poor CYP2C19 activity remains unknown, the
evidence for such selection in CYP2C19 seems to be per-
suasive. The magnitude of the evolutionary pressure ap-
pears to be similar to that exerted on the human genome
by infectious diseases. These environmental and/or physio-
logical forces that shaped the cytochrome repertoire of
modern humans have important consequences for drug
metabolism in the present day [19].
The selective forces that we observed are temporally
linked to the development of systematic agricultural
practices by early humans and CYP2C physiological
functions although it is not possible to infer a direct
causal association from our data. It would be useful to
extend these studies to other populations where different
agricultural practices might have exposed humans to
a different range of potentially harmful environmental
chemical compounds. Similar signatures of selection
might be found for other cytochrome P450 enzymes
that activate known mycotoxins [10,38]. In addition, if
the selective pressure were causally related to the use
of agriculture then we would expect to see low levels of
extended homozygosity in isolated populations that
continued to maintain a ‘hunter gatherer’ lifestyle.
Further work could examine the co-evolution of cyto-
chromes with other elements of the metabolic pathways
involved in detoxification of xenobiotic substances and
metabolism of drugs. Some speculative studies indicate
that considerable synergisms may exist between certain
isoforms of cytochromes and transporter molecules that
regulate influx of their substrates into cells [51]. If this
is the case then patterns of inheritance of phenotype
are likely to be highly complex since drug transporter
status may have a permissive effect on either fast or
Table 1 FST measure of population differentiation and minor allele frequencies at CYP2C19/9 locus in Gambians and in
the three HapMap populations
FST per locus Allele frequency
CYP2C19 Gambians Europeans Asians Yoruba
rs4244285 (CYP2C19*2) 0.016 0.23 0.15 0.27 0.15
rs12248560 (CYP2C19*17) 0.080 0.23 0.21 0.01 0.28
rs4986893 (CYP2C19*3) 0.295 0 0 0.53 0
rs7067866 0.078 0.39 0.57 0.61 0.29
rs4417205 0.011 0.18 0.15 0.27 0.18
rs4986894 0.015 0.18 0.16 0.27 0.14
CYP2C9
rs1799853 (CYP2C9*2) 0.05 0.03 0.09 0 0
Overall 0.098
FSTAT 2.9.3 was used to estimate FST. The genotype data for the individual SNPs of the HapMap populations were retrieved from NCBI dbSNP BUILD 131.
(See figure on previous page.)
Figure 4 Haplotype bifurcation plots and extended haplotype homozygosity diagrams for the CYP2C19*3 slow metabolizing allele in
Asians and the gain-of-function allele CYP2C19*17 in Europeans. The plot is centred on the common, slow metabolizing allele which is
common in Asians CYP2C19*3 at SNP positions rs12778026, rs4986893 (CYP2C19*3) and rs4304692 and EHH was measured away from the core in
Asians. The high activity allele core region in Europeans is focused on SNP positions rs11568732, rs12248560 (CYP2C19*17) and rs4986894 and
the haplotype extension measured from the core locus. A. CYP2C19*3 haplotype structure in Japanese and Han Chinese. The CYP2C19*3 mutation
is carried on haplotype TAA (haplotype 4) which shows some evidence of extended homozygosity. B. CYP2C19*17 haplotype structure in
Europeans. The CYP2C19*17 variant is carried on haplotype TTT (haplotype 4) that extends along the genome without a breakdown of its
homozygosity showing evidence of selection in Europeans. The haplotype table below the figure describes the CYP2C19*17-containing
haplotypes in the European population.
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slow cytochrome metabolism. Thus, in the absence of
linkage disequilibrium, determining genotype at either
locus independently would not reliably predict meta-
bolic phenotype.
Inclusion of longer stretches of the genome in in-
creased numbers of individuals could identify long range
haplotypes in cytochrome gene clusters which have been
positively selected. These haplotypes delimited by rapidly
decaying LD would identify biologically important com-
binations of alleles across the gene cluster [11]. Such
haplotypes could be functionally more important – for
example in drug metabolism – than alleles of the indi-
vidual genes.
Since we have identified some evidence of global evo-
lutionary selective forces in favour of alleles of CYP2C19
that have low activity in the metabolic transformation of
xenobiotic compounds it seems reasonable to suggest
that some environmental agent would be responsible for
exerting this pressure and shaping the cytochrome pro-
file of modern humans. This agent could be a known
substrate for CYP2C19 which has a metabolite with un-
recognised toxic effects or alternatively a known toxin
which is activated by the enzyme by a novel molecular
mechanism. Either of these hypotheses might provide a
fruitful starting point for further biochemical and toxico-
logical research. Such studies might cast further light on
human evolution and could potentially identify sub-
stances not previously known to be toxic.
Conclusions
Many forces shape the topography of the human gen-
ome and strong natural selection resulting from infec-
tious diseases is well–recognised. Here we show that
environmental chemicals could also exert a similar effect
on human evolution.
We speculate that a ubiquitous environmental com-
pound may be rendered toxic by the activity of CYP2C19
and thus early humans with poor CYP2C19 activity had a
survival advantage. This genetic adaptation took place
within the last 10,000 years which coincides with the
development of systematic agricultural practices. These
evolutionary forces, which are of a similar magnitude to
those exerted by infectious diseases, could have arisen
from exposure to a novel toxin perhaps arising from
stored foodstuffs. Selective pressure from this toxin may
have driven allelic differentiation at the CYP2C19 locus
and hence strongly influenced the drug metabolizing pro-
file of modern humans.
Methods
Study participants
Eighty-five Gambian blood donors from Sukuta and
42 from Brikama (Western Region), Njaba Kunda and
Farafenni (Northern Region) gave informed consent
for genetic screening and analysis. The subjects from
Sukuta participated in an investigation of nucleotide
diversity of the TNF gene region [52] and the remain-
der adult cohort participated in a randomised con-
trolled trial of chlorproguanil-dapsone/co-artemether
for uncomplicated malaria [53] (Clinical Trials Identifier:
NCT00118794).
Venous blood was collected in EDTA tubes and de-
oxyribonucleic acid (DNA) extracted using Nucleon
kits BACC3 (Tepnel Life Sciences, Britain) according
to the manufacturer’s protocol. The DNA was quantified
using Picogreen (Molecular Probes®) and the NanoDrop
1000™ spectrophotometer (Thermo Scientific) and stored
at −20°C until required.
Metabolic phenotype for CYP2C19 had been previ-
ously characterized in fine detail in the adult study
group and all common fast and slow metabolizing alleles
identified [19]. TaqMan® drug metabolizing assay mixes
for SNP genotyping were used to screen functional poly-
morphisms and amplification refractory mutation system
PCR to genotype promoter and intronic polymorphisms
in CYP2C19 and CYP2C9 in all the subjects. The 13
SNPs IDs genotyped were:
1. CYP2C19: rs7067866, rs11568729, rs4417205,
rs4986894, rs3758580 (mRNA990 *2A*2B), rs4986893
(mRNA636 *3), rs17884712 (mRNA431 *9), rs4244285
(mRNA681 *2), rs12248560 (*17) and
2. CYP2C9: rs1799853 (*2), rs7900194 (*8), rs2256871
(*9), rs28371686 (*11).
Genotypic data from the two Gambian study groups
were pooled to give a sample size of 127 subjects.
Ethical approval was obtained from the Medical Re-
search Council (MRC) Scientific Coordinating Com-
mittee and the MRC/Gambia Government Joint Ethics
Committee (L2005.80, SCC No. 981 11th January 2005).
Consent was written in English and explained in the
local language of the subjects by an interpreter and the
response was documented in English on the consent
form.
Bifurcation plot and relative extended haplotype
homozygosity diagram construction
First we constructed relative extended haplotype homo-
zygosity (REHH) and haplotype bifurcation plots to look
for positive selection of CYP2C19*2 in the Gambian
population using SWEEP [54]. CYP2C19*3 was not
present in any Gambian participant. Missing allelic data
were filled in using fastPHASE version 2.3 [55]. We then
sought to validate signatures of positive selection ob-
served for Gambian haplotypes using 120 chromosomes
from HapMap population panels initially West African
Yoruba from Nigeria and then Europeans from Utah
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and Asians of Japanese and Han Chinese origin: Inter-
national HapMap Project, HapMap Data Rel 24/phaseII
Nov8, on NCBI B36 assembly, dbSNP b126 [16]. These
data were analysed for haplotype breakdown at the
CYP2C19*2 locus with the core haplotype rs4244285-
rs4417205-rs3758580 and for CYP2C19*3 where it
was present (rs12778026-rs4986893-rs4304692). We
generated REHH and bifurcation plots from rs7067866
(96501916) to rs9332198 (NCBI build35 96731487) for
the Yoruba, to rs1934967 (96731416) for CEU and to
rs9332198 (96731487) for the Han Chinese. These plots
were then examined for signals of selective pressure.
The FST statistic was calculated to summarise allele
frequency differentiation between populations using
FSTAT 2.9.3 [56]. Haplotype diversity was estimated by
coalescent simulations of the genotypic data in DnaSP
5.10.01 after 1000 replicates [57]. The input data con-
sisted of a sample size of 500, simulations given theta
value 12.5 and a pseudorandom number seed 2999311.
Additional file
Additional file 1: Table S1. FST for CYP2C19 alleles across Gambians,
Europeans, Japanese and Han Chinese and Yoruba.
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